Drugs / STK-012
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05098132 | Jan 2022 → Jan 2029 expected | non-small cell lung carcinoma | Synthekine | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 6
| Date | Issuer | Release |
|---|---|---|
| 2026-04-20 | Synthekine | Results Synthekine Presents Updated Clinical and Translational Data Demonstrating Strong Activity for STK-012 in First-Line Non-Squamous NSCLC in Oral Presentation at AACR 2026 synthekine.com ↗
Synthekine, Inc. , a clinical-stage biotechnology company developing precision cytokine therapeutics, today reported updated clinical and translational data for STK-012 in combination with pembrolizumab, pemetrexed, and carboplatin (PCT) in first-line PD-L1-negative, non‑squamous (NSQ) non-small cell lung cancer (NSCLC). |
| 2025-11-06 | Synthekine | Results Synthekine Presents Positive Initial Results from Phase 1a/1b Clinical Trial of STK-012 Plus Pembrolizumab and Chemotherapy in First-Line, PD-L1 Negative Nonsquamous Non-Small Cell Lung Cancer synthekine.com ↗
Synthekine Inc ., an engineered cytokine therapeutics company, today announced positive initial results from a Phase 1a/1b clinical trial of STK-012 in first-line, PD-L1 negative nonsquamous (NSQ) non-small cell lung cancer (NSCLC) in combination with standard of care (SoC) pembrolizumab and chemotherapy (PCT). |
| 2024-11-08 | Synthekine | Results Synthekine Announces Presentation of New Translational Data from Phase 1a/1b Clinical Trial of α/β Biased IL-2, STK-012, at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting synthekine.com ↗ |
| 2024-04-08 | Synthekine | Results Synthekine Presents Positive Initial Results from Phase 1a/1b Clinical Trial of α/β Biased IL-2, STK-012, for Treatment of Advanced Solid Tumors synthekine.com ↗
Of 40 efficacy evaluable subjects, partial response (PR) was observed in 3 (RCC, NSCLC and HNSCC) and 12 had stable disease (SD) as their best overall response (BOR) by RECIST V1.1 |
| 2021-11-16 | Synthekine | Results Synthekine Presents Data at AACR Annual Meeting 2021 Demonstrating Selective IL-2 Partial Agonist, STK-012, Promotes Anti-Tumor Response without Related Toxicities synthekine.com ↗
Synthekine Inc., an engineered cytokine therapeutics company, today announced preclinical data presented at the American Association of Cancer Research Annual Meeting 2021 demonstrating its alpha/beta selective IL-2 partial agonist, STK-012, induced potent anti-tumor activity while avoiding the toxicities that have hindered the development of IL-2 therapeutics, including vascular leak syndrome (VLS). |
| 2021-11-16 | Synthekine | Regulatory Synthekine Advances IL-2 Partial Agonist, STK-012, into Clinical Investigation for Treatment of Solid Tumors synthekine.com ↗
Synthekine Inc., an engineered cytokine therapeutics company, today announced it is advancing its IL-2 partial agonist, STK-012, into clinical investigation following clearance of its investigational new drug (IND) application by the U.S. Food and Drug Administration (FDA). |
All press releases naming this drug 12 releases
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | STK-012 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05098132 ↗ |
| Modality | Protein / enzyme biologic | “Engineered Interleukin-2 (IL-2) selective for antigen activated T cells” NCT05098132 ↗ |
| Route | Subcutaneous | “STK-012 subcutaneous (SC) as monotherapy in selected solid tumor indications” NCT05098132 ↗ |